Tag: osteoporosis

Image: PD 1. Romosozumab, an anti-sclerostin antibody, significantly increased bone mineral density in postmenopausal women compared to placebo.  2. When given monthly at a dose of 210 mg, Romosozumab increased bone mineral density to a greater extent than either alendronate or teriparatide.  Evidence Rating Level: 1 (Excellent)        Study Rundown: Sclerostin...
Image: PD/Tau Protein Alzheimer Disease In this section, we will highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Romosozumab in Postmenopausal Women with Low Bone Mineral Density Current osteoporosis medications increase bone mineral density and prevent the progression of structural damage but may not restore...
Image: PD 1. Pathogenic variants of the plastin 3 (PLS3) gene were identified in five families with X-linked osteoporosis and osteoporotic fractures.   2. A rare PLS3 variant was found to be associated with decreased BMD and increased risk of fracture among elderly heterozygous women.  3. Zebrafish with pls3 knockdown developed skeletal malformations...
Image: PD  1. Repeat bone mineral density (BMD) scans did not meaningfully change risk stratification for major osteoporotic or hip fractures in men and women not undergoing treatment for osteoporosis.  2. Serial BMD scans may not provide clinically meaningful information and may not justify the cost associated with the test.  Evidence Rating...
Image: PD 1. The combination of teriparatide and enosumab increased bone mineral density in postmenopausal women with osteoporosis more than either agent alone.  2. The combination of PTH and a RANKL inhibitor may be a useful option for the prevention of osteoporosis, especially in women at high risk of fracture.  Evidence Rating...